Isoniazid interactions

Anne M. Baciewicz, Timothy H. Self

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Isoniazid is an antitub.erculous drug that is usually administered for nine to 12 months. The potential for clinically important interactions exists because this drug is a potent inhibitor of drug metabolism. Studies and case reports have shown that isoniazid inhibits the metabolism of several drugs, including phenytoin, carbamazepine, anticoagulants, benzodiazepines, and vitamin D. Furthermore, isoniazid inhibits both monoamine oxidase and diamine oxidase (histaminase). Additional study is required to document the clinical significance of other isoniazid interactions. Future investigations will identify new isoniazid interactions.

Original languageEnglish (US)
Pages (from-to)714-718
Number of pages5
JournalSouthern Medical Journal
Volume78
Issue number6
DOIs
StatePublished - Jan 1 1985

Fingerprint

Isoniazid
Amine Oxidase (Copper-Containing)
Pharmaceutical Preparations
Monoamine Oxidase
Carbamazepine
Phenytoin
Benzodiazepines
Vitamin D
Anticoagulants

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Isoniazid interactions. / Baciewicz, Anne M.; Self, Timothy H.

In: Southern Medical Journal, Vol. 78, No. 6, 01.01.1985, p. 714-718.

Research output: Contribution to journalArticle

Baciewicz, AM & Self, TH 1985, 'Isoniazid interactions', Southern Medical Journal, vol. 78, no. 6, pp. 714-718. https://doi.org/10.1097/00007611-198506000-00025
Baciewicz, Anne M. ; Self, Timothy H. / Isoniazid interactions. In: Southern Medical Journal. 1985 ; Vol. 78, No. 6. pp. 714-718.
@article{fffb92c8640b499fa795a14b037d7a09,
title = "Isoniazid interactions",
abstract = "Isoniazid is an antitub.erculous drug that is usually administered for nine to 12 months. The potential for clinically important interactions exists because this drug is a potent inhibitor of drug metabolism. Studies and case reports have shown that isoniazid inhibits the metabolism of several drugs, including phenytoin, carbamazepine, anticoagulants, benzodiazepines, and vitamin D. Furthermore, isoniazid inhibits both monoamine oxidase and diamine oxidase (histaminase). Additional study is required to document the clinical significance of other isoniazid interactions. Future investigations will identify new isoniazid interactions.",
author = "Baciewicz, {Anne M.} and Self, {Timothy H.}",
year = "1985",
month = "1",
day = "1",
doi = "10.1097/00007611-198506000-00025",
language = "English (US)",
volume = "78",
pages = "714--718",
journal = "Southern Medical Journal",
issn = "0038-4348",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Isoniazid interactions

AU - Baciewicz, Anne M.

AU - Self, Timothy H.

PY - 1985/1/1

Y1 - 1985/1/1

N2 - Isoniazid is an antitub.erculous drug that is usually administered for nine to 12 months. The potential for clinically important interactions exists because this drug is a potent inhibitor of drug metabolism. Studies and case reports have shown that isoniazid inhibits the metabolism of several drugs, including phenytoin, carbamazepine, anticoagulants, benzodiazepines, and vitamin D. Furthermore, isoniazid inhibits both monoamine oxidase and diamine oxidase (histaminase). Additional study is required to document the clinical significance of other isoniazid interactions. Future investigations will identify new isoniazid interactions.

AB - Isoniazid is an antitub.erculous drug that is usually administered for nine to 12 months. The potential for clinically important interactions exists because this drug is a potent inhibitor of drug metabolism. Studies and case reports have shown that isoniazid inhibits the metabolism of several drugs, including phenytoin, carbamazepine, anticoagulants, benzodiazepines, and vitamin D. Furthermore, isoniazid inhibits both monoamine oxidase and diamine oxidase (histaminase). Additional study is required to document the clinical significance of other isoniazid interactions. Future investigations will identify new isoniazid interactions.

UR - http://www.scopus.com/inward/record.url?scp=0021815499&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021815499&partnerID=8YFLogxK

U2 - 10.1097/00007611-198506000-00025

DO - 10.1097/00007611-198506000-00025

M3 - Article

C2 - 3890202

AN - SCOPUS:0021815499

VL - 78

SP - 714

EP - 718

JO - Southern Medical Journal

JF - Southern Medical Journal

SN - 0038-4348

IS - 6

ER -